Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.
Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In this study, we employed an integrative...
Saved in:
Main Authors: | Artem Berezovsky, Oluwademilade Nuga, Indrani Datta, Kimberly Bergman, Thais Sabedot, Katherine Gurdziel, Susan Irtenkauf, Laura Hasselbach, Yuling Meng, Claudius Mueller, Emanuel F Petricoin, Stephen Brown, Neeraja Purandare, Sidhesh Aras, Tom Mikkelsen, Laila Poisson, Houtan Noushmehr, Douglas Ruden, Ana C deCarvalho |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0315171 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Temozolomide-Induced Myelodysplasia
by: Ethan A. Natelson, et al.
Published: (2010-01-01) -
Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01) -
Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
by: Sadhak Sengupta, et al.
Published: (2012-01-01) -
Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
by: Ingrid H. Olsen, et al.
Published: (2012-01-01) -
A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
by: Haruko Morokuma, et al.
Published: (2012-01-01)